IV clot-busting medicine for stroke when standard options don’t fit
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether giving IV TNK (tenecteplase) plus standard stroke care can improve outcomes in some people who have a new stroke but cannot get alteplase (another clot-busting drug) and do not have a large blocked artery that can be treated with a procedure. It’s meant for strokes with “mismatch” findings on scans that suggest salvageable brain tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older, and the stroke happened recently (you can start treatment 4.5 to 12 hours after the last time you were well).
- You cannot receive IV alteplase because the stroke started more than 4.5 hours ago.
- Your scans should show no large/proximal artery blockage that would normally be treated with a procedure (like certain parts of the internal carotid artery, MCA M1/dominant M2, or vertebral/basilar arteries).
- Before the stroke, you had little or no disability (mRS 0 to 2).
- Your CT/MRI/angiography and/or blood-flow imaging must show a “mismatch” pattern—small enough core damage and enough affected-but-recoverable brain to meet the trial’s thresholds.
- A brain scan is needed to confirm there is no bleeding in the brain (no intracranial hemorrhage).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatment approaches for a stroke caused by a blocked brain artery: doing a procedure to remove the clot alone versus giving an IV clot-busting medicine first (tenecteplase). It aims to see which approach works better and is safest for improving recovery.
This trial looks at giving a clot-busting medicine directly into the brain arteries (intra-arterial TNK) when a stroke procedure (thrombectomy) doesn’t reopen the blocked vessel enough. It aims to improve recovery by improving blood flow while checking for safety, especially bleeding risk.
This trial tests a clot-busting drug called tenecteplase given directly into the brain artery for people having a moderate stroke caused by a blockage in a medium-sized blood vessel. The goal is to see if it helps improve recovery when given within 24 hours of stroke symptoms starting.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.
This trial tests whether adding a clot-busting medication (rhTNK-tPA) before a clot-removal procedure (thrombectomy) can improve outcomes for people who have a moderate-to-severe stroke and arrive at the hospital 4.5 to 24 hours after symptoms start. It's for those with a large artery blockage but still enough brain tissue that can be saved.
Hear when a new Ischemic Stroke, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.